Hepatotoxicity due to lysine salt of bendazac.

Article Details

Citation
Copy to clipboard

Alcalde M, Garcia-Diaz M, Najarro F, Donoso MS, Cebria L, Pascasio JM

Hepatotoxicity due to lysine salt of bendazac.

Scand J Gastroenterol. 1996 Feb;31(2):206-8.

PubMed ID
8658045 [ View in PubMed
]
Abstract

BACKGROUND: The lysine salt of bendazac is a non-steroidal anti-inflammatory agent, and it is marketed exclusively for the treatment of cataracts. We report two cases of possible hepatotoxicity due to the use of bendazac lysine. METHODS: Laboratory tests, serologic tests, abdominal sonography and scan were performed to study liver disease. RESULTS: Reversible increases of the hepatic enzymes were found in both cases. Anemia was also found in one of the cases (case 1). CONCLUSIONS: Abnormal liver test results could be related to a possible liver injury attributed to the use of bendazac lysine.

DrugBank Data that Cites this Article

Drugs